News
NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has ...
New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.
The Mounjaro KwikPen, a multi-dose, prefilled device for single-patient use, is designed for convenient self-administration.
3h
Zacks Investment Research on MSNNovo Nordisk Rises 6% So Far in August: How to Play the Stock
Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...
Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...
Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results